Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase II Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer.

NCT04775862 is registered in ClinicalTrials.gov with National Guard Health Affairs as lead sponsor.

NCT NCT04775862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04775862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase II Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer.
Lead sponsor
National Guard Health Affairs
Phase
Phase 2
Overall status
Unknown status
Start date
February 21, 2021
Completion date
February 29, 2024
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer